title: Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients.
abstract: Doxorubicin (DOX) and idarubicin (IDA) are anthracycline antibiotics, widely used in human cancer treatment. The present study addressed the effects of these two drugs on lipid bilayer fluidity, protein conformation and microviscosity in erythrocytes from acute myeloid leukaemia patients, using electron spin resonance (ESR) spectroscopy and fluorescence measurements. Only DOX caused statistically significant changes in the parameters examined. Within 30 min of drug injection, changes were observed in the fluidity of the hydrophobic parts of the lipid bilayer and erythrocyte membrane protein conformation. These changes persisted for up to 24h. Analysis of the EPR Tempamine spectrum also showed that the microviscosity of the erythrocyte interior increased during the early stages of the drug effect. Idarubicin, in contrast, caused no identifiable change in any of the parameters studied and therefore seems to be safe for erythrocytes. We conclude that IDA is markedly less toxic than DOX to erythrocytes from acute myeloid leukaemia patients.
authors.affiliation: Department of Thermobiology, University of Łódź, Banacha 12/16 Str., 90-237 Łódź, Poland. aszwar@biol.uni.lodz.pl
authors.forename: Agnieszka
authors.initials: A
authors.lastname: Marczak
authors.forename: Aleksandra
authors.initials: A
authors.lastname: Kowalczyk
authors.forename: Agata
authors.initials: A
authors.lastname: Wrzesień-Kus
authors.forename: Tadeusz
authors.initials: T
authors.lastname: Robak
authors.forename: Zofia
authors.initials: Z
authors.lastname: Jóźwiak
mesh_terms: D000328:Adult; D003497:Cyclic N-Oxides / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology* / Q000627:therapeutic use; D004347:Drug Interactions; D004578:Electron Spin Resonance Spectroscopy; D004910:Erythrocyte Membrane / Q000187:drug effects; D004912:Erythrocytes / Q000187:drug effects*; D006801:Humans; D015255:Idarubicin / Q000494:pharmacology* / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008051:Lipid Bilayers; D008560:Membrane Fluidity / Q000187:drug effects; D008565:Membrane Proteins / Q000378:metabolism; D008875:Middle Aged; D014783:Viscosity / Q000187:drug effects
chemical_list: D003497:Cyclic N-Oxides; D008051:Lipid Bilayers; D008565:Membrane Proteins; C015527:4-amino-TEMPO; D004317:Doxorubicin; D015255:Idarubicin